Review
Immunology
Jeremy D. D. Rubinstein, Maureen M. M. O'Brien
Summary: InO is an antibody drug conjugate used to treat relapsed and refractory B-cell precursor acute lymphoblastic leukemia. It has shown significant activity in both adult and pediatric trials. However, there are notable toxicities including sinusoidal obstruction syndrome and myelosuppression. In the relapsed/refractory setting, the subsequent curative therapy modality must be considered to mitigate these risks.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Geoffrey Shouse, Alex F. Herrera
Summary: Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease typically treated with combination chemotherapy and rituximab. While a majority of patients may be cured with initial treatment, a minority may experience relapse or refractory DLBCL. The emergence of immunotherapies has expanded treatment options, offering the possibility of durable remissions previously unattainable.
Article
Oncology
Nicola Stefano Fracchiolla, Mariarita Sciume, Cristina Papayannidis, Antonella Vitale, Sabina Chiaretti, Mario Annunziata, Fabio Giglio, Prassede Salutari, Fabio Forghieri, Davide Lazzarotto, Monia Lunghi, Annalisa Imovilli, Barbara Scappini, Massimiliano Bonifacio, Michelina Dargenio, Carmela Gurrieri, Elisabetta Todisco, Marzia Defina, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Cerrano, Lidia Santoro, Elena Tagliaferri, Enrico Barozzi, Pasquale De Roberto, Marta Canzi, Elisa Buzzatti, Chiara Sartor, Francesco Passamonti, Robin Foa, Antonio Curti, Thomas Wirth
Summary: This retrospective study evaluated the efficacy and safety of blinatumomab and inotuzumab ozogamicin in the treatment of relapsed B-lymphoblastic leukemia. The study demonstrated the feasibility and effectiveness of sequential immunotherapy using these two drugs in terms of minimal residual disease, overall survival, and disease-free survival.
Article
Hematology
Bachar Samra, Joseph D. Khoury, Kiyomi Morita, Farhad Ravandi, Guillaume Richard-Carpentier, Nicholas J. Short, Siba El Hussein, Philip Thompson, Nitin Jain, Hagop Kantarjian, Elias Jabbour
Summary: This study reports the long-term safety and efficacy of the hyper-CVAD-R regimen in adults with BL and HGBL, focusing on its effectiveness in preventing CNS relapse. The presence of CNS involvement and BM involvement were identified as independent predictors for relapse-free survival and overall survival. The data support the use of hyper-CVAD-R in preventing CNS relapse, especially among high-risk patients with BM or CNS involvement.
Review
Oncology
Elias Jabbour, Shilpa Paul, Hagop Kantarjian
Summary: Advances in cancer biology have led to the development of antibody-drug conjugates (ADCs), which combine the selectivity of therapeutic antibodies with the cytotoxicity of small molecules for targeted therapies. The success of ADCs depends on the specific properties of their components, impacting stability, pharmacokinetics, and antitumor activity. ADCs like gemtuzumab ozogamicin and inotuzumab ozogamicin have provided valuable insights for optimizing these agents for clinical use.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Review
Oncology
Leila Amini, Sara K. Silbert, Shannon L. Maude, Loretta J. Nastoupil, Carlos A. Ramos, Renier J. Brentjens, Craig S. Sauter, Nirali N. Shah, Mohamed Abou-El-Enein
Summary: Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for certain hematological cancers. Successful CAR-T cell infusion requires timely preparation and consideration of various factors. This review provides a summary of the considerations in preparing patients for CAR-T cell therapy and highlights current limitations and future research areas.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Article
Hematology
Jochim Reinert, Antonia Beitzen-Heineke, Klaus Wethmar, Matthias Stelljes, Walter Fiedler, Stefan Schwartz
Summary: This study presents flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. Additionally, comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities are provided.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Chiara Sartor, Mario Arpinati, Gabriella Chirumbolo, Luca Dozza, Gianluca Cristiano, Jacopo Nanni, Giovanni Marconi, Valentina Robustelli, Ilaria Vigliotta, Sarah Parisi, Carolina Terragna, Nicoletta Testoni, Stefania Paolini, Giovanni Martinelli, Antonio Curti, Michele Cavo, Cristina Papayannidis
Summary: Antigen-directed target therapy is now the standard of care for B-cell acute lymphoblastic leukemia. The expression percentage and fluorescent intensity of CD22 on leukemic blast cells have an impact on patient outcomes. Higher CD22-FI is associated with better response rates and overall survival.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Immunology
Randall C. C. Dere, Richard L. L. Beardsley, Dan Lu, Tong Lu, Grace H-W. Ku, Gabriel Man, Van Nguyen, Surinder Kaur
Summary: Polatuzumab vedotin is an antibody-drug conjugate that targets CD79b and delivers an anti-mitotic agent to B cells, showing anti-cancer activity against B-cell malignancies. It has been approved for the treatment of diffuse large B-cell lymphoma in combination with rituximab and bendamustine.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Hematology
Chiara Tarantelli, Francesco Bertoni
Summary: This article discusses the molecular basis of the combination of polatuzumab vedotin and rituximab in the treatment of diffuse large B-cell lymphoma, and provides clues to the potential mechanisms of resistance to this combination therapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Catherine Diefenbach, Brad S. Kahl, Andrew McMillan, Javier Briones, Lalita Banerjee, Raul Cordoba, Fiona Miall, John M. Burke, Jamie Hirata, Yanwen Jiang, Joseph N. Paulson, Yi Meng Chang, Lisa Musick, Pau Abrisqueta
Summary: Obinutuzumab combined with polatuzumab vedotin or lenalidomide showed promising tolerability and activity in previous trials for relapsed or refractory follicular lymphoma. This study aimed to investigate the efficacy of the novel Pola-G-Len combination in enhancing antitumor response. The results demonstrated high complete response rates and support further investigation of Pola-G-Len in a larger patient population.
LANCET HAEMATOLOGY
(2021)
Article
Hematology
Zheng Shi, Yiqian Zhu, Jing Zhang, Baoan Chen
Summary: This review examines the progress of monoclonal antibodies in treating ALL patients and their impact on patient outcomes. The study finds that monoclonal antibodies such as Rituximab and Blinatumomab can prolong remission duration and improve overall survival in ALL patients. The use of these antibodies also shows promise in eliminating minimal residual disease. However, there are concerns regarding the potential toxicity of some antibodies on the liver.
Article
Oncology
Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Goekbuget, Anjali S. Advani, Susan O'Brien, Michaela Liedtke, Akil A. Merchant, Ryan D. Cassaday, Tao Wang, Hui Zhang, Erik Vandendries, Elias Jabbour, David Marks, Hagop M. Kantarjian
Summary: The study demonstrated that InO was more effective than standard intensive chemotherapy for patients with R/R Ph+ ALL, showing higher rates of complete remission and minimal residual disease negativity, as well as improved hematopoietic stem cell transplantation rates. However, there was no significant benefit in overall survival, and the probability of being event-free at 12 months was higher with InO treatment.
Article
Immunology
Katrin Schoenfeld, Julia Harwardt, Jan Habermann, Adrian Elter, Harald Kolmar
Summary: This article presents a novel approach using specific antibody-drug conjugates to eliminate malignant B cells while maintaining a functional adaptive immune system, providing a new method for non-Hodgkin's lymphoma treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Hematology
David Kegyes, Ciprian Jitaru, Gabriel Ghiaur, Stefan Ciurea, Dieter Hoelzer, Ciprian Tomuleasa, Robert Peter Gale
Summary: About half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve complete remission or relapse are not cured by current therapies. Immune therapies, including monoclonal antibodies, BiTEs, ADCs, and CARs, have shown effectiveness in this setting. This manuscript summarizes FDA-approved immune therapies for advanced adult B-ALL, their efficacy, safety, QoL, and future directions.
